Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade

Por Mueller, Antonia MS, Hebb, Jonathan, Sagiv-Barfi, Idit, Marabelle, Aurelien, Houot, Roch, Rajapaksa, Amanda, Czerwinski, Debra K, Chang, Serena, Chester, Cariad, Sadaram, Mohith, Waller, Erin, Levy, Ronald, Kohrt, Holbrook
Publicado no J Immunother Cancer (2014)

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Por Kohrt, Holbrook E., Thielens, Ariane, Marabelle, Aurelien, Sagiv-Barfi, Idit, Sola, Caroline, Chanuc, Fabien, Fuseri, Nicolas, Bonnafous, Cécile, Czerwinski, Debra, Rajapaksa, Amanda, Waller, Erin, Ugolini, Sophie, Vivier, Eric, Romagné, François, Levy, Ronald, Bléry, Mathieu, André, Pascale
Publicado em 2014